Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...

Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and PresidentSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

(RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a loss of 36 cents per share. The biotechnology company posted revenue of $5.2 ...

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

The U.S. private credit market has reached $2.1 trillion in assets under management (AUM) this year, surpassing the ...

31 October 2025 Jacqui Kappler, chief democratic counsel at the US Judiciary Committee, reveals that AI is top of the IP subcommittee’s priorities at a speech in Washington, DC. Sarah Speight reports.